CA2447562A1 — Pirenzepine ophthalmic gel
Assigned to VALLEY FORGE PHARMACEUTICALS Inc · Expires 2002-12-05 · 23y expired
What this patent protects
It is a primary object of the present invention to provide an aqueous ophthalmic formulation, for treating myopia, comprising pirenzepine in combination with a pharmaceutically acceptable gel carrier.
USPTO Abstract
It is a primary object of the present invention to provide an aqueous ophthalmic formulation, for treating myopia, comprising pirenzepine in combination with a pharmaceutically acceptable gel carrier.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.